AT
ATHE.US Alterity Therapeutics Ltd
- Market cap
- USD 37.4M
- P/E
- -
- P/B
- 1.36x
- ROE
- -53.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is ATHE.US undervalued?
Graham numberThe Graham number of Alterity Therapeutics Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Alterity Therapeutics Ltd fundamental analysis
No fundamental analysis for Alterity Therapeutics Ltd yet.
Alterity Therapeutics Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Alterity Therapeutics Ltd
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 tha…
Full company profileAlterity Therapeutics Ltd financial statements
Alterity Therapeutics Ltd annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 132K | 201K | 109K | 412K | 4.34M | 5.12M | 3.92M | 4.02M | 5.44M | 0.00 |
| Gross Profit | 111K | 179K | 78.8K | -112K | 3.98M | 4.76M | 3.63M | 3.80M | 5.31M | -113K |
| Operating Income | -6.88M | -7.77M | -12.7M | -10.4M | -15.2M | -15.5M | -14.6M | -19.6M | -14.6M | -27.8M |
| EBITDA | -6.86M | -11.4M | -12.8M | -13.3M | -15.1M | -17.4M | -14.5M | -19.5M | -14.5M | -27.7M |
| Net Income | -7.54M | -8.27M | -12.0M | -10.1M | -15.3M | -12.8M | -13.8M | -19.1M | -12.1M | -22.9M |
| EPS | -8.48 | -9.29 | -12 | -6.74 | -5.41 | -3.20 | -3.41 | -3.14 | -1.14 | -1.30 |
| Balance Sheet | ||||||||||
| Total Assets | 25.3M | 18.7M | 19.9M | 13.3M | 33.6M | 41.4M | 27.3M | 19.2M | 46.0M | 46.0M |
| Total Liabilities | 1.59M | 2.64M | 3.36M | 2.76M | 3.12M | 5.89M | 4.50M | 5.43M | 3.62M | 3.29M |
| Shareholders' Equity | 23.7M | 16.1M | 16.6M | 10.5M | 30.5M | 35.5M | 22.8M | 13.8M | 42.4M | 42.7M |
| Cash & Short-term Investments | 21.9M | 15.2M | 14.4M | 9.20M | 28.1M | 34.8M | 15.8M | 12.6M | 40.7M | 37.3M |
| Total Debt | 0.00 | 0.00 | 0.00 | 33.7K | 65.6K | 117K | 210K | 159K | 155K | 193K |
| Cash Flow | ||||||||||
| Operating Cash Flow | -5.87M | -6.25M | -14.0M | -9.43M | -17.3M | -12.3M | -20.0M | -12.6M | -11.5M | -22.0M |
| Capital Expenditure | 27.9K | 62.4K | 7.02K | 16.7K | 10.5K | 89.1K | 7.31K | 5.72K | 3.00 | 22.0M |
| Free Cash Flow | -5.89M | -6.31M | -14.0M | -9.45M | -17.3M | -12.4M | -20.0M | -12.6M | -11.5M | -22.5M |
| Ratios | ||||||||||
| ROE | -31.8% | -51.4% | -72.3% | -95.4% | -50.2% | -36.2% | -60.5% | -138.6% | -28.6% | -53.6% |
| ROA | -29.8% | -44.1% | -60.1% | -75.6% | -45.6% | -31.1% | -50.5% | -99.5% | -26.4% | -49.7% |
| Net Profit Margin | -5,696.6% | -4,108.8% | -11,020.8% | -2,444.2% | -352.8% | -250.7% | -352.5% | -475.8% | -223.4% | - |
| Debt to Equity | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.01x | 0.01x | 0.00x | 0.00x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Alterity Therapeutics Ltd dividends
Alterity Therapeutics Ltd has not paid dividends in the last 9 fiscal years.
Last stock split: 1:10 on Jan 9, 2023.
Who owns Alterity Therapeutics Ltd
- Insiders 0.00%
- Institutions 2.09%
- Public & others 97.91%
- Shares outstanding 19.1M
- Free float 14.4M
Top funds holding ATHE.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Nasdaq Composite Index | 1.16K | 0.01% | 0.00% | May 2026 |
Top institutions holding ATHE.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Twin Lakes Capital Management, LLC | 139K | 0.76% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 63.1K | 0.35% | +8.02% | Jun 2026 |
| Greenleaf Trust | 62.0K | 0.34% | +93.75% | Jun 2026 |
| HB Wealth Management, LLC | 58.5K | 0.32% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 37.6K | 0.21% | +87.26% | Jun 2026 |
| HRT FINANCIAL LLC | 17.3K | 0.10% | 0.00% | Jun 2026 |
| BNP Paribas Arbitrage, SA | 10.2K | 0.06% | +50.37% | Jun 2026 |
| GAMMA Investing LLC | 2.31K | 0.01% | +24.41% | Jun 2026 |
| Rhumbline Advisers | 2.01K | 0.01% | +1.98% | Jun 2026 |
| Acadian Asset Management LLC | 1.86K | 0.01% | 0.00% | Jun 2026 |
| Providence Capital Advisors, LLC | 200.00 | 0.00% | 0.00% | Jun 2026 |
| Integrated Wealth Concepts LLC | 73.00 | 0.00% | 0.00% | Jun 2026 |
| Advisor Group Holdings, Inc. | 68.00 | 0.00% | 0.00% | Jun 2026 |
| Ronald Blue Trust, Inc. | 40.00 | 0.00% | 0.00% | Jun 2026 |
| CoreCap Advisors, LLC | 21.00 | 0.00% | 0.00% | Jun 2026 |
| Steward Partners Investment Advisory, LLC | 6.00 | 0.00% | 0.00% | Jun 2026 |
| UBS Group AG | 5.00 | 0.00% | 0.00% | Jun 2026 |
| Caitong International Asset Management Co., Limited. | 1.00 | 0.00% | 0.00% | Jun 2026 |
| Cranbrook Wealth Management, LLC | 1.00 | 0.00% | 0.00% | Jun 2026 |
| Citigroup Inc | 1.00 | 0.00% | 0.00% | Jun 2026 |
Alterity Therapeutics Ltd company profile
- Company name
- Alterity Therapeutics Ltd
- Ticker
- ATHE.US
- Exchange
- USA Stocks
- Listed since
- Sep 5, 2002
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 11
- Fiscal year end
- June
- Address
- 500 Collins Street, Melbourne, VIC, Australia, 3000
- Phone
- 61 3 9349 4906
- Website
- alteritytx.com
About Alterity Therapeutics Ltd
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as bioMUSE, biomarkers of progression in multiple system atrophy. The company also operates drug discovery platform that generates patentable chemical compounds to treat the underlying pathology of neurological diseases. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.
Alterity Therapeutics Ltd management
5- Dr. David A. Stamler M.D.CEO, MD & Director · born 1961
- Ms. Abby Macnish Niven B.Com., B.Sc., C.F.A.CFO & Company Secretary · born 1982
- Dr. Rudolph Emile Tanzi Ph.D.Chief Scientific Advisor and Member of Research & Development Advisory Board · born 1959
- Dr. Steven D. Targum M.D.Chief Medical Advisor
- Dr. Robert ChernyHead of Research